China's Biopharma Industry Will Outperform Its General Medical Industry
This article was originally published in PharmAsia News
Executive SummaryAccording to its 12 Five-year Plan, China will further promote the development of biotechnologies to which the country has independent intellectual property rights
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.